Characteristics of Elderly Patients Initiating Sitagliptin or Non-DPP-4-Inhibitor Oral Antihyperglycemic Agents: Analysis of a Cross-Sectional US Claims Database

por Wang, Tongtong, McNeill, Ann Marie, Chen, Yong, O’Neill, Edward A., Engel, Samuel S.
Publicado 2018

Efficacy and Safety of Sitagliptin in Hispanic/Latino Patients with Type 2 Diabetes: A Pooled Analysis from Ten Randomized, Placebo-Controlled Phase 3 Clinical Trials

por Raji, Annaswamy, Long, Jianmin, Lam, Raymond L. H., O’Neill, Edward A., Engel, Samuel S.
Publicado 2018

Erratum to: Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

por Ommen, Elizabeth S., Xu, Lei, O’Neill, Edward A., Goldstein, Barry J., Kaufman, Keith D., Engel, Samuel S.
Publicado 2015

Comparison of Treatment with Sitagliptin or Sulfonylurea in Patients with Type 2 Diabetes Mellitus and Mild Renal Impairment: A Post Hoc Analysis of Clinical Trials

por Ommen, Elizabeth S., Xu, Lei, O’Neill, Edward A., Goldstein, Barry J., Kaufman, Keith D., Engel, Samuel S.
Publicado 2015

A Randomized, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Adding Omarigliptin to Antihyperglycemic Therapies in Japanese Patients with Type 2 Diabetes and Inadeq...

por Gantz, Ira, Okamoto, Taro, Ito, Yuka, Sato, Asako, Okuyama, Kotoba, O’Neill, Edward A., Engel, Samuel S., Lai, Eseng
Publicado 2017

Efficacy and Safety of Sitagliptin Compared with Dapagliflozin in People ≥ 65 Years Old with Type 2 Diabetes and Mild Renal Insufficiency

por Raji, Annaswamy, Xu, Zhi Jin, Lam, Raymond L. H., O’Neill, Edward A., Kaufman, Keith D., Engel, Samuel S.
Publicado 2020

A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2...

por Gantz, Ira, Okamoto, Taro, Ito, Yuka, Okuyama, Kotoba, O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado 2017

A randomised, double‐blind, trial of the safety and efficacy of omarigliptin (a once‐weekly DPP‐4 inhibitor) in subjects with type 2 diabetes and renal impairment

por Chacra, Antonio, Gantz, Ira, Mendizabal, Geraldine, Durlach, Lucila, O'Neill, Edward A., Zimmer, Zachary, Suryawanshi, Shailaja, Engel, Samuel S., Lai, Eseng
Publicado 2017

A randomized, placebo-controlled study of the cardiovascular safety of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus

por Gantz, Ira, Chen, Menghui, Suryawanshi, Shailaja, Ntabadde, Catherine, Shah, Sukrut, O’Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Lai, Eseng
Publicado 2017

A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoS...

por Scott, Russell, Morgan, Jerry, Zimmer, Zachary, Lam, Raymond L. H., O'Neill, Edward A., Kaufman, Keith D., Engel, Samuel S., Raji, Annaswamy
Publicado 2018

A randomized, placebo‐controlled trial to assess the efficacy and safety of sitagliptin in Japanese patients with type 2 diabetes and inadequate glycaemic control on ipragliflozin...

por Seino, Yutaka, Kaku, Kohei, Kadowaki, Takashi, Okamoto, Taro, Sato, Asako, Shirakawa, Masayoshi, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.
Publicado 2021

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin

por Kaku, Kohei, Kadowaki, Takashi, Seino, Yutaka, Okamoto, Taro, Shirakawa, Masayoshi, Sato, Asako, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D.
Publicado 2021

Randomized clinical trial comparing the efficacy and safety of treatment with the once‐weekly dipeptidyl peptidase‐4 (DPP‐4) inhibitor omarigliptin or the once‐daily DPP‐4 inhibito...

por Goldenberg, Ronald, Gantz, Ira, Andryuk, Paula J., O'Neill, Edward A., Kaufman, Keith D., Lai, Eseng, Wang, Yin Na, Suryawanshi, Shailaja, Engel, Samuel S.
Publicado 2017

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequ...

por Lee, Seung-Hwan, Gantz, Ira, Round, Elizabeth, Latham, Melanie, O’Neill, Edward A., Ceesay, Paulette, Suryawanshi, Shailaja, Kaufman, Keith D., Engel, Samuel S., Lai, Eseng
Publicado 2017

A randomized, placebo‐controlled study to evaluate the efficacy and safety of adding omarigliptin to insulin therapy in Japanese patients with type 2 diabetes and inadequate glycae...

por Kadowaki, Takashi, Seino, Yutaka, Kaku, Kohei, Okamoto, Taro, Kameya, Miho, Sato, Asako, Hirano, Tomona, Oshima, Nobuyuki, Gantz, Ira, O'Neill, Edward A., Engel, Samuel S.
Publicado 2021

Randomized clinical trial of the safety and efficacy of sitagliptin and metformin co‐administered to Chinese patients with type 2 diabetes mellitus

por Ji, Linong, Han, Ping, Wang, Xiaoyue, Liu, Jingdong, Zheng, Shaoxiong, Jou, Ying‐Ming, O'Neill, Edward A, Golm, Gregory T, Engel, Samuel S, Kaufman, Keith D, Shankar, R Ravi
Publicado 2016

Double‐blind, randomized clinical trial assessing the efficacy and safety of early initiation of sitagliptin during metformin uptitration in the treatment of patients with type 2 d...

por Frias, Juan P., Zimmer, Zachary, Lam, Raymond L.H., Amorin, Guillermo, Ntabadde, Catherine, Iredale, Carol, O'Neill, Edward A., Engel, Samuel S., Kaufman, Keith D., Makimura, Hideo, Crutchlow, Michael F.
Publicado 2019

Double‐blind, randomized clinical trial comparing the efficacy and safety of continuing or discontinuing the dipeptidyl peptidase‐4 inhibitor sitagliptin when initiating insulin gl...

por Roussel, Ronan, Duran‐García, Santiago, Zhang, Yilong, Shah, Suneri, Darmiento, Carolyn, Shankar, R. Ravi, Golm, Gregory T., Lam, Raymond L. H., O'Neill, Edward A., Gantz, Ira, Kaufman, Keith D., Engel, Samuel S.
Publicado 2018

Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control

por Bays, Harold E, Brinton, Eliot A, Triscari, Joseph, Chen, Erluo, Maccubbin, Darbie, MacLean, Alexandra A, Gibson, Kendra L, Ruck, Rae Ann, Johnson-Levonas, Amy O, O’Neill, Edward A, Mitchel, Yale B
Publicado 2015

Orally Bioavailable Macrocyclic Peptide That Inhibits Binding of PCSK9 to the Low Density Lipoprotein Receptor

por Johns, Douglas G., Campeau, Louis-Charles, Banka, Puja, Bautmans, An, Bueters, Tjerk, Bianchi, Elisabetta, Branca, Danila, Bulger, Paul G., Crevecoeur, Inne, Ding, Fa-Xiang, Garbaccio, Robert M., Guetschow, Erik D., Guo, Yan, Ha, Sookhee N., Johnston, Jennifer M., Josien, Hubert, Kauh, Eunkyung A., Koeplinger, Kenneth A., Kuethe, Jeffrey T., Lai, Eseng, Lanning, Christine L., Lee, Anita Y.H., Li, Li, Nair, Anilkumar G., O’Neill, Edward A., Stoch, S. Aubrey, Thaisrivongs, David A., Tucker, Thomas J., Vachal, Petr, van Dyck, Kristien, Vanhoutte, Frederic P., Volckaert, Bram, Wolford, Dennis G., Xu, Andy, Zhao, Tian, Zhou, Dan, Zhou, Susan, Zhu, Xiaohong, Zokian, Hratch J., Walji, Abbas M., Wood, Harold B.
Publicado 2023